spike
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
consid
major
antigen
vaccin
design
previous
demonstr
receptorbind
domain
rbd
residu
protein
contain
multipl
conformationdepend
neutral
epitop
conf
vi
serv
major
target
sarscov
neutral
character
antigen
structur
rbd
panel
novel
mab
isol
mice
immun
inactiv
sarscov
vaccin
ten
rbdspecif
mab
map
four
distinct
group
conform
epitop
design
group
potent
neutral
activ
proteinpseudotyp
sar
virus
group
b
c
mab
target
epitop
may
overlap
previous
character
conf
iii
vi
respect
display
differ
capac
block
receptor
bind
group
mab
direct
uniqu
epitop
competit
bind
two
antirbd
mab
recogn
linear
epitop
group
e
map
rbd
residu
respect
none
inhibit
receptor
bind
viru
entri
surprisingli
neutral
epitop
group
c
could
complet
disrupt
singl
amino
acid
substitut
eg
delet
sever
amino
acid
ntermin
ctermin
region
rbd
howev
group
epitop
sensit
mutat
highlight
import
vaccin
develop
data
provid
import
inform
understand
antigen
immunogen
sarscov
panel
novel
mab
use
tool
studi
structur
protein
guid
sar
vaccin
design
voir
potenti
applic
bioterror
agent
need
develop
effect
vaccin
sarscov
remain
high
import
sinc
emerg
sar
number
candid
vaccin
use
varieti
approach
develop
start
point
inactiv
sarscov
consid
one
major
vaccin
candid
sever
inactiv
sar
vaccin
prepar
convent
protocol
eg
betapropiolacton
formaldehyd
uv
light
test
preclin
studi
kill
whole
viru
vaccin
effect
term
see
front
matter
sever
acut
respiratori
syndrom
sar
fatal
emerg
infecti
diseas
caus
novel
coronaviru
sarscov
recent
studi
suggest
sarscov
zoonot
may
broad
host
rang
besid
human
although
recent
sar
outbreak
seriou
concern
remain
reemerg
anim
reser
induc
neutral
antibodi
protect
immun
sever
anim
model
howev
antigen
immunogen
properti
inactiv
sarscov
remain
character
special
identifi
character
antigen
epitop
induc
protect
immun
prioriti
develop
safe
effect
sar
vaccin
similar
coronavirus
sarscov
envelop
positivestrand
rna
viru
featur
larg
viral
genom
encod
vial
replicas
protein
major
structur
protein
consist
spike
nucleocapsid
n
membran
small
envelop
protein
e
sever
small
protein
unknown
function
although
viral
protein
immunogen
elicit
immun
respons
vaccin
anim
protein
sarscov
type
transmembran
glycoprotein
provid
virion
coronalik
appear
consid
major
antigen
vaccin
develop
sever
live
viru
dna
vaccin
express
protein
induc
steril
immun
sarscov
infect
sarscov
initi
bind
protein
function
receptor
angiotensinconvert
enzym
express
target
cell
acid
discret
fragment
residu
within
put
subunit
protein
character
minim
receptorbind
domain
rbd
coincid
rbd
sarscov
protein
also
major
target
neutral
antibodi
sever
conformationdepend
epitop
capabl
induc
highli
potent
neutral
antibodi
character
rbd
previous
show
inactiv
sarscov
vaccin
could
induc
high
titer
antibodi
protein
immun
anim
importantli
rbdspecif
antibodi
contribut
major
seramedi
neutral
activ
studi
isol
panel
rbdspecif
mab
inactiv
vaccineimmun
mice
determin
respons
epitop
neutral
antibodi
result
provid
import
inform
design
sar
vaccin
sarscov
strain
access
number
propag
vero
cell
describ
previous
briefli
infect
cell
harvest
complet
lyse
three
cycl
freezethaw
sigmaaldrich
st
loui
mo
ad
lysat
ratio
incub
c
h
inactiv
viru
centrifug
rpm
min
remov
cell
debri
supernat
desalt
sephadex
concentr
filtrat
sepharosecl
sequenti
inactiv
sarscov
final
prepar
puriti
analyz
hplc
confirm
observ
coronaviruslik
particl
electron
microscop
determin
reactiv
convalesc
sera
sar
patient
western
blot
plasmid
encod
truncat
fragment
correspond
subunit
residu
receptorbind
domain
residu
sarscov
access
number
fuse
fc
portion
human
respect
design
rbdfc
respect
kindli
provid
dr
farzan
harvard
medic
school
boston
rbdfc
mutant
gener
mutagenesi
use
quickchang
xl
kit
strategen
verifi
dna
sequenc
recombin
fusion
protein
express
cell
transfect
plasmid
use
fugen
reagent
boehring
mannheim
indianapoli
accord
manufactur
protocol
purifi
protein
sepharos
fast
flow
amersham
bioscienc
piscataway
nj
fulllength
protein
fl
extracellular
domain
ec
truncat
amino
acid
sarscov
urbani
access
number
express
expressf
insect
cell
recombin
baculoviru
protein
scienc
corpor
bridgeport
ct
protein
express
serumfre
cell
line
purifi
appar
homogen
puriti
shown
bind
solubl
set
peptid
overlap
protein
rbd
sequenc
sarscov
strain
peptid
contain
residu
nine
residu
overlap
adjac
peptid
synthes
gene
gateway
llc
hayward
ca
previous
describ
standard
solidphas
fmoc
method
use
peptid
synthesi
peptid
purifi
homogen
puriti
highperform
liquid
chromatographi
hplc
identifi
laser
desorpt
mass
spectrometri
four
balbc
mice
week
old
subcutan
immun
g
inactiv
sarscov
vaccin
resuspend
pb
plu
mlp
tdm
adjuv
sigma
saint
loui
mi
boost
g
antigen
plu
mlptdm
adjuv
interv
preimmun
sera
collect
start
immun
antisera
collect
day
boost
sera
kept
c
use
hybridoma
produc
antirbd
mab
gener
use
standard
protocol
previous
describ
briefli
spleenocyt
immun
mice
harvest
fuse
myeloma
cell
cell
cultur
supernat
well
contain
hybridoma
coloni
screen
enzymelink
immunosorb
assay
elisa
use
rbdfc
coat
antigen
cell
posit
well
expand
retest
cultur
remain
posit
subclon
gener
stabl
hybridoma
cell
line
mab
purifi
cultur
supernat
protein
sepharos
fast
flow
amersham
bioscienc
isotyp
mab
determin
mous
monoclon
antibodi
isotyp
kit
amersham
bioscienc
reactiv
mous
sera
mab
variou
protein
determin
elisa
briefli
gml
recombin
protein
use
coat
microtit
plate
corn
costar
acton
carbon
buffer
ph
c
overnight
block
nonfat
milk
serial
dilut
mous
sera
mab
ad
incub
c
h
follow
three
wash
pb
contain
tween
bound
antibodi
detect
hrpconjug
goat
antimous
igg
zyme
laboratori
c
h
follow
wash
reaction
visual
addit
substrat
tetramethylbenzidin
tmb
absorb
nm
measur
elisa
plate
reader
tecan
us
research
triangl
park
nc
determin
effect
disulfid
bond
reduct
bind
antirbd
mab
elisa
plate
coat
recombin
rbdfc
concentr
gml
treat
h
c
dithiothreitol
dtt
concentr
mm
follow
wash
well
treat
mm
iodoacetamid
h
c
wash
standard
elisa
perform
describ
competit
elisa
perform
determin
inhibitori
activ
antirbd
mab
bind
biotinyl
mab
rbdfc
briefli
well
elisa
plate
coat
rbdfc
describ
mixtur
contain
gml
unlabel
mab
gml
biotinyl
mab
ad
follow
incub
c
h
bind
biotinyl
mab
detect
addit
hrpconjug
streptavidin
zyme
laboratori
tmb
sequenti
biotinyl
mab
perform
use
ezlink
nhspeo
solid
phase
biotinyl
kit
pierc
rockford
il
accord
manufactur
protocol
sarscov
pseudoviru
system
develop
laboratori
previous
describ
brief
cell
cotransfect
plasmid
encod
protein
plasmid
encod
envdefect
luciferaseexpress
genom
use
fugen
reagent
boehring
mannheim
supernat
contain
sar
pseudovirus
harvest
h
posttransfect
use
singlecycl
infect
human
civet
cell
briefli
cell
plate
cellswel
tissuecultur
plate
grown
overnight
supernat
contain
pseudoviru
preincub
serial
dilut
mab
c
h
addit
cell
cultur
refe
fresh
medium
h
later
incub
addit
h
cell
wash
pb
lyse
use
lysi
reagent
includ
luciferas
kit
promega
madison
wi
aliquot
cell
lysat
transfer
costar
flatbottom
luminomet
plate
corn
costar
corn
ny
follow
addit
luciferas
substrat
promega
rel
light
unit
rlu
determin
immedi
ultra
luminomet
tecan
us
inhibit
antirbd
mab
rbdfc
bind
cell
measur
flow
cytometri
previous
describ
briefli
cell
detach
collect
wash
hank
balanc
salt
solut
hbss
sigma
st
loui
mo
rbdfc
ad
cell
final
concentr
gml
presenc
absenc
gml
mab
follow
incub
room
temperatur
min
cell
wash
hbss
incub
antihuman
iggfitc
conjug
zyme
dilut
room
temperatur
addit
min
wash
cell
fix
formaldehyd
pb
analyz
fac
canto
flow
cytomet
bd
bioscienc
mountain
view
ca
use
fac
diva
softwar
inactiv
sarscov
prepar
betapropiolacton
purifi
puriti
describ
four
balbc
mice
subcutan
immun
inactiv
virus
presenc
mlp
tdm
adjuv
use
recombin
fl
rbdfc
antigen
elisa
measur
antibodi
respons
specif
protein
rbd
respect
show
fig
b
four
mice
develop
signific
antibodi
protein
rbd
first
boost
immun
serum
reactiv
titer
appar
increas
subsequ
boost
titer
rbdspecif
antibodi
determin
elisa
shown
fig
antirbd
antibodi
mous
antisera
collect
day
third
boost
reach
mean
endpoint
titer
result
confirm
rbd
protein
inactiv
sar
vaccin
highli
immunogen
elicit
specif
antibodi
consist
previou
find
character
rbdbase
antigen
epitop
present
inactiv
vaccin
prepar
gener
panel
rbdspecif
mab
immun
mice
fu
antigen
coat
elisa
plate
gml
mab
test
gml
valu
consid
posit
reaction
highlight
boldfac
b
control
mab
target
domain
ing
mous
splenocyt
myeloma
cell
screen
hybridoma
use
rbdfc
antigen
tabl
specif
antirbd
mab
determin
elisa
set
sarscov
antigen
includ
recombin
subunit
truncat
extracellular
domain
ec
fulllength
protein
fl
antirbd
mab
react
rbdfc
also
ec
fl
tabl
suggest
may
target
epitop
present
nativ
protein
mab
bound
rbd
ec
fl
effect
reduc
bind
could
due
alter
epitop
conform
result
lack
trimet
associ
protein
interest
note
two
mab
rel
weaker
reactiv
ec
impli
epitop
may
well
expos
two
protein
major
mab
reactiv
nativ
rbdfc
dttreduc
rbdfc
indic
target
disulfid
bonddepend
conform
epitop
express
rbd
protein
fig
interestingli
mab
bound
strongli
nativ
weakli
reduc
rbdfc
suggest
epitop
conformationdepend
linear
sequenc
may
involv
mab
lower
reactiv
recombin
extracellular
domain
recogn
nativ
reduc
rbdfc
equal
suggest
target
linear
epitop
within
rbd
use
proteinpseudotyp
sar
pseudovirus
sensit
quantit
singlecycl
infect
assay
measur
neutral
activ
newli
isol
antirbd
mab
shown
fig
mab
specif
conforn
epitop
could
neutral
sar
pseudovirus
neutral
dose
rang
fig
reactiv
antirbd
mab
nativ
dttreduc
rbdfc
measur
elisa
antigen
coat
gml
mab
test
gml
gml
four
antirbd
mab
exhibit
potent
neutral
activ
lower
panel
mab
also
react
weakli
reduc
antigen
gml
contrast
two
mab
direct
linear
epitop
concentr
high
gml
could
neutral
proteinmedi
viru
entri
therefor
inactiv
sarscov
vaccin
could
induc
high
titer
rbdspecif
antibodi
potent
neutral
activ
consist
previous
find
neutral
antibodi
primarili
direct
conform
epitop
rbd
set
overlap
peptid
cover
rbd
sequenc
protein
use
antigen
elisa
local
epitop
newli
isol
antirbd
mab
expect
none
conformationdepend
mab
includ
react
test
peptid
data
shown
two
mab
recogn
dttreduc
rbdfc
react
one
peptid
respect
fig
react
peptid
ylrhgklrpferdisnv
overlap
previous
character
epitop
nonneutr
mab
isol
rbdfcimmun
mice
suggest
linear
site
immunogen
inactiv
viru
recombin
rbdfc
immunogen
react
peptid
svyawerkkisncvadi
locat
ntermin
region
rbd
thu
linear
epitop
fine
local
overlap
peptid
epitop
specif
panel
antirbd
mab
map
bind
competit
assay
four
mab
biotinyl
bind
activ
rbdfc
respect
measur
presenc
absenc
unlabel
antirbd
mab
shown
tabl
five
mab
divid
competit
group
sinc
compet
two
biotinyl
mab
similar
pattern
three
mab
group
group
b
abil
compet
biotinyl
mab
compet
three
biotinyl
mab
design
group
c
mab
interestingli
mab
abl
inhibit
bind
four
biotinyl
mab
rbdfc
suggest
recogn
distinct
epitop
group
two
linear
epitopespecif
mab
could
compet
conformationspecif
mab
therebi
design
group
e
mab
result
suggest
rbd
protein
present
inactiv
sarscov
fig
epitop
map
mab
overlap
peptid
cover
rbd
protein
elisa
peptid
coat
gml
mab
test
gml
vaccin
contain
sever
differ
antigen
epitop
capabl
induc
specif
antibodi
immun
mice
previous
identifi
six
group
conformationdepend
epititop
conf
ivi
rbd
panel
mab
isol
mice
immun
rbdfc
epitop
specif
newli
isol
antirbd
mab
character
bind
competit
assay
measur
inhibitori
activ
bind
previous
biotinyl
mab
tabl
five
group
mab
character
compet
biotinyl
conf
mab
suggest
epitop
may
overlap
conf
epitop
three
group
b
mab
classifi
conf
iiilik
mab
sinc
compet
biotinyl
conf
iii
mab
mab
group
c
abl
compet
conf
vi
mab
outstandingli
mab
group
compet
biotinyl
mab
compet
previous
character
biotinyl
mab
suggest
recogn
uniqu
novel
epitop
design
conf
vii
similarli
two
mab
specif
linear
epitop
significantli
compet
biotinyl
mab
furthermor
none
new
antirbd
mab
bind
competit
pattern
similar
previous
character
conf
ii
iv
v
mab
suggest
three
group
epitop
may
immunogen
inactiv
virusimmun
mice
compet
mab
test
gml
abil
block
bind
biotinyl
mab
rbdfc
elisa
greater
inhibit
consid
posit
competit
valu
bold
neg
number
indic
increas
bind
biotinyl
reagent
crystal
structur
rbd
bound
reveal
residu
rbd
form
receptorbind
motif
rbm
previous
show
conf
iii
vi
mab
could
effici
partial
block
receptorbind
conf
ii
determin
whether
newli
isol
antirbd
mab
inhibitori
activ
receptor
bind
similar
flow
cytometrybas
assay
use
measur
bind
rbdfc
human
express
cell
presenc
antirbd
mab
shown
fig
rbdfc
abl
bind
cell
bind
could
effici
partial
block
repres
antirbd
mab
group
b
group
c
mab
higher
potenc
compar
correspond
conf
iii
vi
control
mab
respec
tive
fig
unexpectedli
group
mab
also
abl
partial
inhibit
receptorbind
except
highest
capac
compet
conf
mab
signific
inhibitori
activ
similar
conf
mab
result
impli
group
ac
epitop
may
ident
previous
character
rather
may
epitop
overlap
term
competit
bind
therefor
mab
group
b
c
also
name
conf
iii
vilik
mab
respect
tabl
similar
group
mab
group
mab
also
weakli
inhibit
bind
rbdfc
fig
contrast
none
two
linear
epitopedepend
mab
block
associ
rbdfc
data
suggest
inactiv
sarscov
vaccin
induc
rbdspecif
antibodi
primarili
target
receptorbind
motif
rbm
use
panel
rbdfc
mutant
map
conform
epitop
rbd
first
assess
reactiv
antirbd
mab
two
truncat
rbdfc
strikingli
major
neutral
epitop
group
ac
complet
disrupt
delet
sever
amino
acid
nterminu
residu
cterminu
residu
rbd
tabl
indic
nand
ctermin
sequenc
essenti
maintain
proper
conform
neutral
epitop
howev
epitop
group
affect
nand
ctermin
delet
suggest
epitop
resid
within
residu
rbd
constrain
conform
fulllength
rbd
set
rbdfc
fusion
protein
bear
specif
point
mutat
conserv
basic
acid
residu
produc
use
elisa
map
epitop
fig
bind
competit
conf
v
mab
inhibit
compet
antirbd
mab
bind
biotinyl
mab
rbdfc
measur
elisa
compet
mab
test
gml
inhibit
calcul
antirbd
mab
interestingli
even
singl
amino
acid
substitut
residu
could
abolish
group
b
c
epitop
tabl
substitut
sever
damag
epitop
group
mab
react
weakli
react
two
mutant
moreov
epitop
mab
group
b
sensit
substitut
regardless
epitop
sensit
singl
mutat
indic
highli
stabl
conserv
motif
rbd
notic
linear
epitop
residu
knock
substitut
comparison
substitut
impact
conform
linear
epitop
rbd
recent
found
conf
iv
vi
mab
similar
reaction
pattern
group
c
mab
rbd
mutant
wherea
reactiv
conf
v
mab
similar
mab
significantli
affect
mutat
tabl
therefor
determin
whether
could
compet
conf
v
mab
bind
interestingli
could
inhibit
bind
biotinyl
conf
v
mab
rbdfc
howev
bind
rbdfc
could
dramat
enhanc
conf
v
mab
fig
contrast
three
conf
v
mab
abl
effici
block
bind
two
biotinyl
conf
v
mab
result
indic
conf
v
mab
target
two
independ
conform
epitop
bind
conf
v
mab
may
result
increas
exposur
epitop
sinc
sudden
appear
sar
focus
studi
character
antigen
immunog
sarscov
effort
develop
safe
effect
vaccin
previous
demonstr
sarscov
inactiv
could
induc
high
titer
neutral
antibodi
primarili
target
receptorbind
region
rbd
protein
fine
map
neutral
epitop
rbd
isol
panel
novel
rbdspecif
mab
mice
immun
inactiv
sarscov
vaccin
use
mab
probe
studi
found
major
antirbd
mab
possess
potent
neutral
activ
sar
pseudoviru
suggest
rbd
protein
inactiv
sarscov
vaccin
retain
nativ
conform
induc
predominantli
neutral
antibodi
previous
identifi
six
group
conformationdepend
neutral
epitop
conf
vi
rbd
use
set
rbdspecif
mab
isol
mice
immun
independ
foldedrbd
conf
iii
vi
epitop
may
overlap
receptorbind
motif
rbm
correspond
mab
effici
partial
block
receptor
bind
similar
bind
competit
assay
conformationspecif
antirbd
mab
isol
mice
immun
inactiv
sarscov
vaccin
map
four
distinct
epitop
group
demonstr
rbd
contain
multipl
conformationdepend
neutral
epitop
half
conformationspecif
mab
recogn
group
epitop
may
overlap
previous
character
conf
epitop
major
neutral
epitop
present
independ
foldedrbd
suggest
epitop
group
conf
mab
better
immunogen
epitop
whole
inactiv
virus
independ
fold
rbd
immonogen
howev
group
epitop
conf
epitp
might
ident
even
could
compet
differ
competit
effici
biotinyl
mab
tabl
differ
capac
block
receptor
bind
fig
group
b
c
mab
recogn
epitop
may
overlap
previous
character
conf
iii
vi
epitop
respect
higher
potenc
inhibit
associ
rbd
accord
uniqu
bind
competit
pattern
group
mab
recogn
novel
conform
neutral
epitop
rbd
data
suggest
rbd
inactiv
viru
recombin
protein
might
display
differ
immunogen
thu
allow
isol
neutral
mab
recogn
differ
conformationdepend
epitop
howev
none
mab
target
conf
ii
iv
v
epitop
isol
inactiv
sarscovimmun
mice
suggest
epitop
might
immunodomin
even
function
inactiv
vaccin
conf
iv
v
epitop
may
overlap
receptorbind
motif
rbd
induc
potent
neutral
antibodi
function
present
immunogen
critic
sar
vaccin
possibl
viral
inactiv
procedur
may
affect
antigen
structur
neutral
epitop
protein
sarscov
thu
limit
abil
induc
neutral
antibodi
consist
previou
find
mab
target
linear
epitop
rbd
neutral
activ
rbd
sarscov
protein
well
expos
surfac
virion
respons
attach
bind
receptor
howev
recent
found
linear
epitop
rbd
unlik
conform
epitop
well
expos
protein
express
transfectedcel
shown
flow
cytometri
assay
data
shown
provid
evid
explain
linear
epitopespecif
mab
neutral
sarscov
rbd
present
protein
aminoacid
fragment
show
high
degre
structur
complex
contain
seven
cystein
five
essenti
receptor
bind
sever
critic
residu
rbd
character
determin
sarscov
receptor
adapt
palm
civet
human
crystal
structur
rbd
bound
human
reveal
sever
disulfid
bond
connect
cystein
form
loop
residu
constitut
receptorbind
motif
rbm
conformationdepend
epitop
rbd
may
determin
complex
structur
recent
report
abil
fulllength
protein
induc
neutral
antibodi
could
abolish
singlepoint
mutat
conserv
amino
acid
residu
rbd
eg
indic
immunogen
protein
highli
determin
rbd
configur
map
critic
residu
rbdbase
neutral
epitop
gener
panel
rbd
mutant
substitut
delet
conserv
amino
acid
residu
surpris
find
group
c
conform
epitop
similar
conf
iv
vi
epitop
could
disrupt
singl
amino
acid
substitut
eg
delet
sever
amino
acid
ctermin
region
rbd
howev
group
epitop
like
conf
v
epitop
sensit
delet
mutat
interest
note
substitut
could
impact
antigen
epitop
significantli
even
though
abolish
function
bind
result
suggest
particularli
conserv
rbd
residu
essenti
maintain
antigen
integr
rbd
epitop
within
rbd
uniqu
although
group
conf
v
mab
similar
pattern
reaction
mutant
appar
direct
differ
epitop
first
compet
bind
second
conf
v
mab
complet
block
receptorbind
margin
inhibitori
activ
local
character
group
conf
v
epitop
provid
import
inform
ration
design
sar
vaccin
first
gener
sar
vaccin
inactiv
sarscov
vaccin
test
preclin
clinic
studi
shown
capac
elicit
steril
immun
sever
anim
model
result
indic
although
major
neutral
domain
sarscov
function
inactiv
vaccin
prepar
import
neutral
epitop
eg
conf
iv
v
may
properli
present
compar
present
recombin
rbd
molecul
vigil
taken
applic
inactiv
vaccin
human
sinc
viral
particl
contain
number
compon
may
induc
harm
immun
andor
inflammatori
respons
believ
rbd
sarscov
protein
may
serv
better
candid
develop
safe
effect
vaccin
sinc
function
region
mediat
receptorbind
viru
entri
contain
multipl
epitop
induc
highli
potent
neutral
antibodi
addit
rbdbase
vaccin
safe
manufactur
compar
inactiv
sarscov
